Surface plasmon resonance imaging-based biosensor for multiplex and ultrasensitive detection of NSCLC-associated exosomal miRNAs using DNA programmed heterostructure of Au-on-Ag

Wu, Wenwen; Yu, Xiaolin; Wu, Jiangling; Wu, Tao; Fan, Yunpeng; Chen, Wenqin; Zhao, Min; Wu, Haiping; Li, Xinmin; Ding, Shijia

doi:10.1016/j.bios.2020.112835

Cited by 72 publications

(40 citation statements)

References 38 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…With the development of DNA nanotechnology, FNAs are widely used to construct a variety of sensing platforms during sample analysis 120 . There have been tremendous researches in FNAs-based biosensors for the detection of DNA, protein and nucleic acids 121 , 122 , 123 , 124 , 125 , 126 . One of the major obstacles for the biosensor design depends on the restricted target accessibility at the solid water interface.…”

Section: Fnas For Drug Analysismentioning

confidence: 99%

Pharmaceutical applications of framework nucleic acids

Liang

Zhang²,

Lin³

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

DNA is a biological polymer that encodes and stores genetic information in all living organism. Particularly, the precise nucleobase pairing inside DNA is exploited for the self-assembling of nanostructures with defined size, shape and functionality. These DNA nanostructures are known as framework nucleic acids (FNAs) for their skeleton-like features. Recently, FNAs have been explored in various fields ranging from physics, chemistry to biology. In this review, we mainly focus on the recent progress of FNAs in a pharmaceutical perspective. We summarize the advantages and applications of FNAs for drug discovery, drug delivery and drug analysis. We further discuss the drawbacks of FNAs and provide an outlook on the pharmaceutical research direction of FNAs in the future.

show abstract

Section: Fnas For Drug Analysismentioning

confidence: 99%

Pharmaceutical applications of framework nucleic acids

Liang

Zhang²,

Lin³

et al. 2022

Acta Pharmaceutica Sinica B

View full text Add to dashboard Cite

show abstract

“…This enabled the detection of twelve different EV membrane proteins using antibodies. Signals were further amplified by attaching anti-CD63-modified gold nanostars to captured EVs and utilizing the plasmonic coupling of these to the underlying gold surface [114][115][116]. The authors showed the clinical potential of this approach using ascitic fluid from 20 patients with ovarian cancer and 20 controls.…”

Section: Spr Arraysmentioning

confidence: 99%

Multiplexed Profiling of Extracellular Vesicles for Biomarker Development

Jiang

Liu

et al. 2021

Nano-Micro Lett.

View full text Add to dashboard Cite

Extracellular vesicles (EVs) are cell-derived membranous particles that play a crucial role in molecular trafficking, intercellular transport and the egress of unwanted proteins. They have been implicated in many diseases including cancer and neurodegeneration. EVs are detected in all bodily fluids, and their protein and nucleic acid content offers a means of assessing the status of the cells from which they originated. As such, they provide opportunities in biomarker discovery for diagnosis, prognosis or the stratification of diseases as well as an objective monitoring of therapies. The simultaneous assaying of multiple EV-derived markers will be required for an impactful practical application, and multiplexing platforms have evolved with the potential to achieve this. Herein, we provide a comprehensive overview of the currently available multiplexing platforms for EV analysis, with a primary focus on miniaturized and integrated devices that offer potential step changes in analytical power, throughput and consistency.

show abstract

“…However, information is scarce in this field, and specific conflicts must be resolved [108]. An SPRi-based biosensor was designed to investigate the simultaneous detection of multiplex 24 NSCLC-associated exosomal miRNAs in a clinical sample employing Au-on-Ag heterostructure and DNA tetrahedral framework (DTF) [49]. This biosensor has a detection range of 2 fM to 20 nM and a detection limit of 1.68 fM.…”

Section: Surface Plasmon Resonance Biosensors (Spr)mentioning

confidence: 99%

Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC)

et al. 2021

View full text Add to dashboard Cite

Globally, non-small cell lung cancer (NSCLC) is the leading cause of cancer deaths. Despite advancements in chemotherapy and targeted therapies, the 5-year survival rate has remained at 16% for the past forty years. Minimal residual disease (MRD) is described as the existence of either isolated tumour cells or circulating tumour cells in biological liquid of patients after removal of the primary tumour without any clinical signs of cancer. Recently, liquid biopsy has been promising as a non-invasive method of disease monitoring and treatment guidelines as an MRD marker. Liquid biopsy could be used to detect and assess earlier stages of NSCLC, post-treatment MRD, resistance to targeted therapies, immune checkpoint inhibitors (ICIs) and tumour mutational burden. MRD surveillance has been proposed as a potential marker for lung cancer relapse. Principally, biosensors provide the quantitative analysis of various materials by converting biological functions into quantifiable signals. Biosensors are usually operated to detect antibodies, enzymes, DNA, RNA, extracellular vesicles (EVs) and whole cells. Here, we present a category of biosensors based on the signal transduction method for identifying biosensor-based biomarkers in liquid biopsy specimens to monitor lung cancer treatment.

show abstract

Surface plasmon resonance imaging-based biosensor for multiplex and ultrasensitive detection of NSCLC-associated exosomal miRNAs using DNA programmed heterostructure of Au-on-Ag

Cited by 72 publications

References 38 publications

Pharmaceutical applications of framework nucleic acids

Pharmaceutical applications of framework nucleic acids

Multiplexed Profiling of Extracellular Vesicles for Biomarker Development

Liquid Biopsy-Based Biosensors for MRD Detection and Treatment Monitoring in Non-Small Cell Lung Cancer (NSCLC)

Contact Info

Product

Resources

About